Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)
Br J Dermatol, 2020.
Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, Marsden A, Evans I, Warren RB, Stocken D, Barker JN; Burden AD, Smith CH; BADBIR study group and the PSORT consortium.
Read publication: Br J Dermatol
Related
Uptake of tumour necrosis factor - alpha inhibitor biosimilars for psoriasis: A drug utilisation stu...
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Sec...
Risk of Major Cardiovascular Events in Patients With Psoriasis Receiving Biologic Therapies: A Prosp...
0 Comments